We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+6.12%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.93B
AUM Growth
-$220M
(-10%)
Cap. Flow
-$774M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
34.72%
Holding
143
New
28
Increased
19
Reduced
29
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
+$75.2M |
| 2 |
Humana
HUM
|
+$40.6M |
| 3 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
+$30.6M |
| 4 |
DaVita
DVA
|
+$28.5M |
| 5 |
INFI
Infinity Pharmaceuticals, Inc.
INFI
|
+$25.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$51.8M |
| 2 |
AstraZeneca
AZN
|
+$48.2M |
| 3 |
AbbVie
ABBV
|
+$45M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$35M |
| 5 |
THOR
THORATEC CORPORATION
THOR
|
+$33.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 46.08% |
| 2 | Financials | 1.16% |
| 3 | Technology | 0.74% |
| 4 | Industrials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HMSY
76
DELISTED
HMS Holdings Corp.
HMSY
| $1.31M | 0.07% |
+57,800
| New | +$1.25M |
|
|
ECYT
77
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $1.2M | 0.06% |
111,967
+61,537
| +122% | +$679K |
|
|
VIRX
78
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $1.19M | 0.06% |
+1,190
| New | +$1.23M |
|
79
Amgen
AMGN
$197B
| $1.14M | 0.06% |
+10,000
| New | +$1.14M |
|
|
ARTC
80
DELISTED
ARTHROCARE CORP
ARTC
| $805K | 0.04% |
+20,000
| New | +$741K |
|
81
Savara
SVRA
$1.13B
| $678K | 0.04% |
20,946
-16,686
| -44% | -$536K |
|
82
Option Care Health
OPCH
$3.42B
| $518K | 0.03% |
17,506
-294,754
| -94% | -$8.33M |
|
83
HCA Healthcare
HCA
$82.2B
| $477K | 0.02% |
+10,000
| New | +$462K |
|
|
BEAT
84
DELISTED
BioTelemetry, Inc.
BEAT
| $437K | 0.02% |
+55,000
| New | +$513K |
|
|
SEM
85
DELISTED
Select Medical
SEM
| $341K | 0.02% |
+54,566
| New | +$266K |
|
|
IMRS
86
DELISTED
IMRIS INC COMMON SHARES (CANADA)
IMRS
| $305K | 0.02% |
+192,051
| New | +$285K |
|
|
87
Teva Pharmaceuticals
TEVA
$36.1B
| $200K | 0.01% |
5,000
-887,759
| -99% | -$35M |
|
88
Xtant Medical Holdings
XTNT
$63.1M
| $196K | 0.01% |
3,265
-3,166
| -49% | -$202K |
|
|
OREX
89
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $122K | 0.01% |
2,169
-89
| -4% | -$5K |
|
|
90
AbbVie
ABBV
$448B
| – | – |
-1,005,000
| Closed | -$45M |
|
91
Agios Pharmaceuticals
AGIO
$2.38B
| – | – |
-151,050
| Closed | -$4.22M |
|
92
Alnylam Pharmaceuticals
ALNY
$36.4B
| – | – |
-383,158
| Closed | -$24.5M |
|
93
AngioDynamics
ANGO
$567M
| – | – |
-2,013,104
| Closed | -$26.6M |
|
|
94
AstraZeneca
AZN
$255B
| – | – |
-928,000
| Closed | -$48.2M |
|
95
Bruker
BRKR
$8.55B
| – | – |
-21,000
| Closed | -$434K |
|
96
Cardinal Health
CAH
$52.9B
| – | – |
-325,000
| Closed | -$16.9M |
|
97
Cross Country Healthcare
CCRN
$428M
| – | – |
-1,343,464
| Closed | -$8.12M |
|
98
Community Health Systems
CYH
$440M
| – | – |
-861,203
| Closed | -$29.5M |
|
99
CALL
Edwards Lifesciences
EW
$48.9B
| – | – |
-1,200,000
| Closed | -$13.9M |
|
|
HOLX
100
DELISTED
Hologic
HOLX
| – | – |
-96,330
| Closed | -$1.99M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q4 2013 Portfolio in Review
As of Q4 2013, Deerfield Management held 143 positions worth $1.93B, down 10% from $2.15B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Deerfield Management withdrew a net $774M in Q4 2013, closing 37 positions and reducing 29 holdings. Its most notable exit was Pfizer, an estimated $51.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 52% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Humana worth $42.8M.
- Deerfield Management's largest Q4 2013 buy was Humana: 414,670 shares worth $42.8M.
- Deerfield Management added most to QUESTCOR PHARMA INC in Q4 2013, an estimated $75.2M increase.
- Deerfield Management's biggest Q4 2013 reduction was Teva Pharmaceuticals, cutting an estimated $35M.
- Deerfield Management fully exited Pfizer in Q4 2013, selling an estimated $51.8M.
- Deerfield Management's ten largest holdings make up 35% of its $1.93B portfolio in Q4 2013.
- Deerfield Management opened 28 new positions and closed 37 in Q4 2013.
- Deerfield Management's portfolio value fell 10% quarter-over-quarter to $1.93B.
Based on Deerfield Management's 13F filing for Q4 2013, filed 14 Feb 2014.